Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain

Artelo Biosciences, Inc. recently announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium in Salamanca, Spain.

The presentation, titled ART26.12, a Novel Fatty Acid-Binding Protein 5 Inhibitor, Shows Efficacy in Breast Cancer-Induced Bone Pain, highlights the effectiveness of ART26.12 in reducing pain behaviors induced by breast cancer in preclinical studies. This new data is from the fourth in a series of preclinical pain models that demonstrated similar activity with ART26.12. Specifically, effective doses and plasma exposures in the breast cancer bone pain study are consistent with previously published data of ART26.12 in oxaliplatin-induced peripheral neuropathy (https://www.jpain.org/article/S1526-5900(24)00345-6/fulltext).

“ART26.12 continues to deliver positive preclinical efficacy data to support its development as a novel non-opioid, non-steroidal analgesic treatment,” stated Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo. “We continue to be impressed with the consistent activity and efficacious dose levels of ART26.12 in multiple animal models of pain and painful neuropathies, whether caused by cancer, diabetes, or multiple chemotherapies. We look forward to initiating human trials with ART26.12 subject to Artelo’s Investigational New Drug application acceptance by the US FDA.”

Breast cancer, the most common cancer in women, spreads to bone more frequently than other parts of the body. More than half people with advanced stage breast cancer experience bone metastasis, often leading to debilitating pain, fractures, and spinal cord compression. ART26.12, Artelo’s potent and selective FABP5 inhibitor, represents a new approach to treating pain associated with cancer where few effective therapies with minimal adverse effects exist.

Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy (CIPN). ART26.12 and other proprietary compounds from Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, and anxiety disorders.

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information, visit www.artelobio.com.